肺癌耐药性研究的可视化分析
|
摘要
目的:研究分析我国肺癌耐药性研究的现状和发展趋势,以期为进一步开展该领域研究提供借鉴。方法:计算机检索中国生物医学文献数据库、中国知网、万方数据库与肺癌耐药性研究相关的文献至2018年1月。由2位研究者按照纳入与排除标准独立筛选出符合标准的研究,用BICOMS 2分析软件对关键词、作者及其单位等信息进行抽取和整理并生成共现矩阵及词篇矩阵,同时,分别利用NetDraw 2.089和gCLUTO 1.0绘制网络关系图和进行聚类分析。结果:初检获得肺癌耐药性研究相关文献2 932篇,最终纳入相关研究1 250篇,研究数量在发表时间、省份、刊载期刊、作者及其单位分布方面很不平衡,作者分为10个主要的研究团体,有33个省、自治区、直辖市和特别行政区的作者参与了肺癌耐药性的研究,同时研究主题主要涵盖4个方面。结论:我国肺癌耐药性研究起步早,2006年以后明显增加,2014年达到高峰,近三年均不超过每年100篇。参与肺癌耐药性研究的作者主要来自北京市、上海市、江苏省、广东省等发达地区,虽研究作者和机构众多,但多产作者和研究机构数量少,目前的研究热点主要集中在对肺癌耐药性的机制研究上。
OBJECTIVE To investigate and analyze the current situation and development trend of studies regarding lung cancer drug resistance published by Chinese scholars in order to provide reference for further research in this field. METHODS CNKI, Wanfang Data and CBM were searched for eligible studies on drug resistance of lung cancer up to January, 2018.Two researchers independently reviewed the articles according to inclusion and exclusion criteria. BICOMS 2 analysis software was used to extract and sort out the keywords, authors and their units, and generate co-occurrence matrices and word matrices. At the same time, NetDraw 2.089 and gCLUTO 1.0 were used to plot network relationship diagrams and cluster analysis respectively. RESULTS 2932 studies about the drug resistance of lung cancer were obtained and 1250 related studies were finally included. The quantity of the research was not balanced in terms of publication time, the provinces, the periodicals, authors and their units. The authors were divided into 10 major research groups. Authors from 33 provinces, autonomous regions, municipalities directly under the Central Government and special administrative regions participated in the study of lung cancer drug resistance. At the same time, the subject mainly covered four aspects. CONCLUSION Research on drug resistance of lung cancer in China started early. It increased significantly since 2006,peaked in 2014, and did not exceed 100 articles per year in the past three years.Meanwhile, the authors of the study on drug resistance of lung cancer mainly come from Beijing, Shanghai, Jiangsu, Guangdong and other developed regions. Although there are many authors and institutions involved, but the number of prolific authors and research institutions is small.Various provinces, cities, research institutes and researchers should strengthen contac and cooperation. The current research focuses mainly on the mechanism of lung cancer drug resistance.
OBJECTIVE To investigate and analyze the current situation and development trend of studies regarding lung cancer drug resistance published by Chinese scholars in order to provide reference for further research in this field. METHODS CNKI, Wanfang Data and CBM were searched for eligible studies on drug resistance of lung cancer up to January, 2018.Two researchers independently reviewed the articles according to inclusion and exclusion criteria. BICOMS 2 analysis software was used to extract and sort out the keywords, authors and their units, and generate co-occurrence matrices and word matrices. At the same time, NetDraw 2.089 and gCLUTO 1.0 were used to plot network relationship diagrams and cluster analysis respectively. RESULTS 2932 studies about the drug resistance of lung cancer were obtained and 1250 related studies were finally included. The quantity of the research was not balanced in terms of publication time, the provinces, the periodicals, authors and their units. The authors were divided into 10 major research groups. Authors from 33 provinces, autonomous regions, municipalities directly under the Central Government and special administrative regions participated in the study of lung cancer drug resistance. At the same time, the subject mainly covered four aspects. CONCLUSION Research on drug resistance of lung cancer in China started early. It increased significantly since 2006,peaked in 2014, and did not exceed 100 articles per year in the past three years.Meanwhile, the authors of the study on drug resistance of lung cancer mainly come from Beijing, Shanghai, Jiangsu, Guangdong and other developed regions. Although there are many authors and institutions involved, but the number of prolific authors and research institutions is small.Various provinces, cities, research institutes and researchers should strengthen contac and cooperation. The current research focuses mainly on the mechanism of lung cancer drug resistance.
引文
[1] Rosell R, Bivona TG, Karachaliou N. Genetics and biomarkers in personalisation of lung cancer treatment [J]. Lancet, 2013, 382(9893): 720-731.
[2] Field JK, Oudkerk M, Pedersen JH, et al. Prospects for population screening and diagnosis of lung cancer [J]. Lancet, 2013, 382(9893):732-741.
[3] Huber RM, Reck M, Thomas M. Current status of and future strategies for multimodality treatment of unresectable stage Ⅲ nonsmall cell lung cancer [J]. Eur Respir J, 2013, 42(4): 1119-1133.
[4] Bidoli P, Zilembo N, Cortinovis D, et al. Randomized phase Ⅱ three-arm trial with three platinum-based doublets in metastatic non-small-cell lung cancer. An Italian Trials in Medical Oncology study [J]. Ann Oncol, 2007, 18(3): 461-467.
[5] Vilmar A, Sorensen JB. Excision repair cross-complementation group 1(ERCC1) in platinum-based treatment of non-small cell lung cancer with special emphasis on carboplatin: a review of current literature [J]. Lung cancer, 2009, 64(2): 131-139.
[6] Kang HK, Um SW, Jeong BH, et al. The utility of endobronchial ultrasound-guided transbronchial needle aspiration in patients with small-cell lung cancer [J]. Intern Med, 2016, 55(9): 1061-1066.
[7] Tartarone A, Lerose R, Aieta M. Somatostatin analog therapy in small cell lung cancer [J]. Semin Nucl Med, 2016, 46(3): 239-242.
[8] Yu CJ, Ou JH, Wang ML, et al. Elevated survivin mediated multidrug resistance and reduced apoptosis in breast cancer stem cells [J]. J Buon, 2015, 20(5): 1287-1294.
[9] Cui L, Liu W,Yan L, et al. Development of a text mining system based on the co-occurrence of bibliographic items in literature databases [J]. New Technol Lib Inf Ser (现代图书情报技术),2008,(8):70-75.
[2] Field JK, Oudkerk M, Pedersen JH, et al. Prospects for population screening and diagnosis of lung cancer [J]. Lancet, 2013, 382(9893):732-741.
[3] Huber RM, Reck M, Thomas M. Current status of and future strategies for multimodality treatment of unresectable stage Ⅲ nonsmall cell lung cancer [J]. Eur Respir J, 2013, 42(4): 1119-1133.
[4] Bidoli P, Zilembo N, Cortinovis D, et al. Randomized phase Ⅱ three-arm trial with three platinum-based doublets in metastatic non-small-cell lung cancer. An Italian Trials in Medical Oncology study [J]. Ann Oncol, 2007, 18(3): 461-467.
[5] Vilmar A, Sorensen JB. Excision repair cross-complementation group 1(ERCC1) in platinum-based treatment of non-small cell lung cancer with special emphasis on carboplatin: a review of current literature [J]. Lung cancer, 2009, 64(2): 131-139.
[6] Kang HK, Um SW, Jeong BH, et al. The utility of endobronchial ultrasound-guided transbronchial needle aspiration in patients with small-cell lung cancer [J]. Intern Med, 2016, 55(9): 1061-1066.
[7] Tartarone A, Lerose R, Aieta M. Somatostatin analog therapy in small cell lung cancer [J]. Semin Nucl Med, 2016, 46(3): 239-242.
[8] Yu CJ, Ou JH, Wang ML, et al. Elevated survivin mediated multidrug resistance and reduced apoptosis in breast cancer stem cells [J]. J Buon, 2015, 20(5): 1287-1294.
[9] Cui L, Liu W,Yan L, et al. Development of a text mining system based on the co-occurrence of bibliographic items in literature databases [J]. New Technol Lib Inf Ser (现代图书情报技术),2008,(8):70-75.